In July 2024, representatives from Singapore’s Health Sciences Authority (HSA) visited Ko Da Pharmaceutical’s headquarters and GMP-certified manufacturing site in Taoyuan, Taiwan.

During the visit, HSA officials gained insights into Ko Da’s approach to modernizing Chinese medicine, its robust quality control systems, and its advanced traceability mechanisms. The visit reinforced mutual understanding in regulatory cooperation and product registration processes. Ko Da’s efforts in maintaining high manufacturing standards were well recognized and appreciated.

🔗 [Read More]